RobertABayerMD
Hematology • Dekalb, ILMyeloproliferative Disorder Hematology-Oncology
Hematology Medical Oncology
Dr. Bayer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Health Services Dr
Ste 1
Dekalb, IL 60115Phone+1 815-756-5255Fax+1 815-756-9944
Summary
- Dr. Robert Bayer is a hematologist in Dekalb, IL and is affiliated with multiple hospitals in the area, including Northwestern Medicine Delnor Hospital, Northwestern Medicine Central DuPage Hospital, and Northwestern Medicine Kishwaukee Hospital. He received his medical degree from McGaw Medical Center of Northwestern University and has been in practice 33 years. He also speaks multiple languages, including German. He specializes in myeloproliferative disorder hematology-oncology and is experienced in esophageal cancer, colorectal cancer, pancreatic cancer, lung cancer, and prostate cancer.
Education & Training
Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1984 - 1987
Northwestern University The Feinberg School of MedicineClass of 1984
Certifications & Licensure
IL State Medical License 1986 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
- S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
- Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer Start of enrollment: 2020 Oct 01
Publications & Presentations
PubMed
- Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy.Dominic J Vitello, Dhavan Shah, Amy Wells, Larissa Masnyk, Madison Cox
Annals of Surgery. 2024-10-14 - 2 citationsProspective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.Dhavan Shah, Amy Wells, Madison Cox, Kevin Dawravoo, John Abad
Annals of Surgery. 2024-01-23 - 17 citationsSequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma.Pamela B Allen, Xinyan Lu, Qing Chen, Kaitlyn O'Shea, Joan S Chmiel
Blood Advances. 2023-06-27
Professional Memberships
- Member
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
